Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 18 pseudogene 64 (KRT18P64) is a non-functional genomic element, part of a family of keratin pseudogenes found in the human genome[4]. These pseudogenes share sequence similarity with functional keratin genes, such as keratin 18 (KRT18), but do not code for proteins and are not involved in known cellular or disease pathways. Pseudogenes like KRT18P64 may have arisen during evolution by duplication or retrotransposition, but there is no evidence they are expressed or serve as therapeutic targets[4]. Clarification: - KRT18P64 is not a receptor, enzyme, or drug target. - The functional gene in this family is keratin 18 (KRT18), which does have well-defined roles in cell structure, apoptosis, and disease biomarker applications[2][3][5], but KRT18P64 itself is a *pseudogene* and does not play these roles. - No evidence supports its use as a biomarker, drug target, or its involvement in any pathological process. Summary: KRT18P64 is a non-coding pseudogene, not a protein or therapeutic target. If you meant the functional role or targeting of keratin 18 (KRT18), please specify, as KRT18 has substantial relevance in disease and therapy, whereas KRT18P64 does not[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin 18 pseudogene 64 (KRT18P64).